Perceptive Advisors LLC
- SEC CIK
- 0001224962
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 16, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 107
- +2 vs. Q1 2024
- Portfolio value
- $4.14B
- −$1.53B (−27.0%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PCVXVaxcyte, Inc. | COM | 1,862,608 | $140.6M | 3.4% | −70,151−3.6% | Reduced | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 3,446,579 | $141.5M | 3.4% | +178,000+5.4% | Added | History |
| NUVLNuvalent, Inc. | COM | 2,549,077 | $193.4M | 4.7% | −234,377−8.4% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 25,933,142 | $208.0M | 5.0% | +6,660,151+34.6% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 3,889,739 | $214.7M | 5.2% | −43,817−1.1% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 28,057,456 | $278.3M | 6.7% | 00.0% | Unchanged | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 10,794,876 | $441.4M | 10.7% | 00.0% | Unchanged | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2024 (18)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| INBXInhibrx Biosciences, Inc. | COM | 4,256,104 | $148.8M | 2.6% | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 6,825,395 | $145.5M | 2.6% | History |
| SRPTSarepta Therapeutics, Inc. | COM | 525,683 | $68.1M | 1.2% | History |
| LABPLandos Biopharma, Inc. | COM NEW | 1,486,991 | $31.9M | 0.6% | History |
| TMCITreace Medical Concepts, Inc. | COM | 2,304,954 | $30.1M | 0.5% | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 4,330,745 | $27.6M | 0.5% | History |
| RVMDRevolution Medicines, Inc. | COM | 618,885 | $19.9M | 0.4% | History |
| ABBVAbbVie Inc. | Stock | 106,500 | $19.4M | 0.3% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 339,012 | $17.0M | 0.3% | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,223,472 | $11.0M | 0.2% | History |
| MORFMorphic Holding, Inc. | COM | 288,221 | $10.1M | 0.2% | History |
| COGTCogent Biosciences, Inc. | COM | 883,333 | $5.94M | 0.1% | History |
| IBRXImmunityBio, Inc. | COM | 1,052,887 | $5.65M | 0.1% | History |
| MGNXMacrogenics Inc | COM | 378,327 | $5.57M | 0.1% | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 82,299 | $4.19M | 0.1% | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 175,000 | $4.14M | 0.1% | History |
| KURAKura Oncology, Inc. | COM | 48,200 | $1.03M | <0.1% | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 300,000 | $852.0K | <0.1% | History |